Leveraging segmentation-guided spatial feature embedding for overall survival prediction in glioblastoma with multimodal magnetic resonance imaging
View abstract on PubMed
Summary
This summary is machine-generated.Accurately predicting glioblastoma survival is vital. Our novel segmentation-guided deep learning method improves overall survival prediction using multimodal MRI, outperforming baseline approaches.
Area Of Science
- Neuro-oncology
- Medical Imaging Analysis
- Machine Learning
Background
- Glioblastoma has a poor prognosis, with a five-year survival rate under 5%.
- Accurate overall survival (OS) prediction is critical for effective glioblastoma treatment planning.
Purpose Of The Study
- To develop a novel deep learning framework for predicting glioblastoma patient overall survival (OS) using multimodal magnetic resonance imaging (MRI).
- To leverage brain tumor segmentation to enhance OS prediction accuracy.
Main Methods
- A segmentation-guided regression method was proposed, utilizing a pre-trained brain tumor segmentation network.
- The survival regression network was jointly trained, focusing on tumor voxels and suppressing background noise.
- The framework employed a UNETR++ backbone and incorporated contrastive loss for improved performance.
Main Results
- The proposed framework achieved a Dice score of 0.7910, Spearman correlation of 0.4112, and Harrell's concordance index of 0.6488.
- The model demonstrated superior performance compared to baseline methods on BraTS and UCSF-PDGM datasets.
- Ablation studies confirmed that pre-training the segmentation network and using contrastive loss significantly improved OS prediction metrics.
Conclusions
- A joint learning framework utilizing a pre-trained segmentation backbone and brain tumor segmentation maps was successfully developed for OS prediction.
- The model's spatial feature map enables a sliding-window approach, adaptable to varying input image resolutions and matrix sizes.
- This approach offers a promising tool for improving survival prediction in glioblastoma patients.

